Pharmaceutical Technology

SEPTEMBER 2, 2022

The rate of drug approvals could be on the rise. In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. increase over the 2016–2020 period average. De-risking drug launch.

Food and Drug Administration 52

Food and Drug Administration Pharma Medicine Distribution 52

European Pharmaceutical Review

JANUARY 19, 2023

With the skills, experience and networks they will gain… in the Winn Award Program, [the programme participants] will make a significant difference in how healthcare is delivered in the US,” stated Jude Ngang, Executive Director, and leader of the Amgen Representation in Clinical Research (RISE) programme.

Food and Drug Administration 79

Food and Drug Administration Physicians Medicine Food 79

Legacy MEDSearch

AUGUST 8, 2022

MicroPort Navibot has received 510(K) clearance from the Food and Drug Administration (FDA) in the United States for the SkyWalker System, the company’s first robot-assisted platform for orthopedic applications. NaviBot is subsidiary of MicroPort MedBot. About MicroPort MedBot Shanghai MicroPort MedBot (Group) Co.,

Food and Drug Administration 98

Food and Drug Administration Recruitment Medical Food 98

European Pharmaceutical Review

JULY 21, 2023

A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. Globalisation and supply chain complexity are a factor.

Pharmaceutical 93

Pharmaceutical Food and Drug Administration Transportation Manufacturing 93

European Pharmaceutical Review

SEPTEMBER 2, 2022

An RMP is submitted as part of the dossier of all new drug applications and is evaluated by regulatory authorities before authorisation is given. Jouaville: Most RMM effectiveness studies are formatted as surveys or drug utilisation studies (DUS). European Network for Health Technology Assessment EMA. References.

Food and Drug Administration 73

Food and Drug Administration Medicine Safety Food 73

European Pharmaceutical Review

FEBRUARY 14, 2024

The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics.

Food and Drug Administration 75

Food and Drug Administration Manufacturing Engineering Pharmacology 75

European Pharmaceutical Review

JUNE 27, 2023

At MaaT Pharma our donor-derived products are made through pooling (ie, mixing multiple donors), thus achieving a higher overall richness and standardisation of the resulting drug product. Conversely, in the US, it has always been clear and regulated as a drug. The plant is set to be operational before the end of 2023.

Food and Drug Administration 96

Food and Drug Administration Manufacturing Medicine Pharma 96

Clarify Health

OCTOBER 26, 2021

Food and Drug Administration (FDA) released guidance entitled, Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. J National Comprehensive Cancer Network. To advance equity in clinical research, the U.S. 2] Figure 1.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

Pharmaceutical Technology

JUNE 5, 2023

The US Food and Drug Administration (FDA) granted final approval to the therapy in May 2023. The regulatory approval was based on the findings from the pivotal Phase III REST-ON clinical trial completed in March 2020.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical Specialization Food 98

Nixon Gwilt Law

DECEMBER 16, 2021

We also speak, network, and learn at various conferences throughout the year. Rounding it all out is our podcast on the Slice of Healthcare network called Decoding Healthcare Innovation. (So So much so that we’ve recently welcomed 20-year Food and Drug Law veteran and FDA expert Mark Mansour, Esq., Don’t wait!

Healthcare 52

Healthcare Healthcare Food and Drug Administration Ethics 52

Legacy MEDSearch

JUNE 22, 2023

Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. ” This latest FDA clearance for the EyeArt v2.2.0

FDA 52

FDA Food and Drug Administration Recruitment Marketing 52

World of DTC Marketing

MARCH 17, 2022

9, 2020, by the Breast Cancer Research and Treatment journal. According to the American Cancer Society Cancer Action Network: Majorities of cancer patients and survivors say they were unprepared for what the costs of their care would be, and most report making major changes to their lifestyle or finances as a result. sustaining life)?

Food and Drug Administration 255

Food and Drug Administration Medical Ethics Patients 255

European Pharmaceutical Review

JANUARY 16, 2023

This also occupies a large resource, given the US Food and Drug Administration (FDA) requirement for double plate checking using a second ‘independent’ person. The FDA is doing this through the publications of Guidance for Industry. .” For example, in September 2022, the company Rebiotix, Inc.

Pharmaceutical 125

Pharmaceutical Food and Drug Administration Manufacturing FDA 125

Pharmaceutical Technology

NOVEMBER 15, 2022

Paxlovid first hit the shelves in the US last December after the Food and Drug Administration (FDA) granted the treatment an emergency use authorisation (EUA). A relapse of symptoms following a period of improvement after treatment with Paxlovid has been described in several papers over the last few months.

Food and Drug Administration 64

Food and Drug Administration Government Distribution FDA 64

European Pharmaceutical Review

DECEMBER 15, 2022

Compared to conventional antidepressant therapy that consists of daily oral administration, psilocybin therapy acts through a single-dose capsule, with repeated administration being investigated in COMPASS’ larger Phase III study. 2020 [Cited 2022Nov]. Late-stage developments in psilocybin therapy. Available from: [link].

Food and Drug Administration 69

Food and Drug Administration Healthcare Healthcare Food 69

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration 75

Food and Drug Administration Safety Patients Leads 75

Pharmaceutical Technology

JUNE 30, 2022

More than 100 clinical trials were initiated in Georgia from 2020 to 2021, with the majority from international sponsors and a focus on managing Phase II-III multinational trials. Bolkvadze predicts that another challenge may be found in the increased volume of operations, leading to a capacity shortage.

Food and Drug Administration 52

Food and Drug Administration Distribution Recruitment Transportation 52

Pharmaceutical Technology

MARCH 22, 2023

During the pandemic, the shortage of basic drugs such as paracetamol in key EU countries led to growing calls to push local drug manufacturing to ensure a smooth supply and to minimise shortages. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Government Pharmaceutical 105

World of DTC Marketing

APRIL 7, 2022

According to a new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN), a majority of patients and survivors say they were unprepared for the costs of their care both in terms of their ability to pay for it (54%) and in what they thought it would cost (64%). Launch prices of new cancer drugs in the U.S.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215